We are live on ! Find out more
CKPT

Checkpoint Therapeutics

Delisted

CKPT was delisted on the 29th of May, 2025.

43 hedge funds and large institutions have $11.2M invested in Checkpoint Therapeutics in 2023 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more capital invested

Capital invested by funds: $6.68M → $11.2M (+$4.51M)

60% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 10

57% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 7

10% more funds holding

Funds holding: 3943 (+4)

2.6% more ownership

Funds ownership: 18.8%21.4% (+2.6%)

1% less call options, than puts

Call options by funds: $493K | Put options by funds: $496K

Holders
43
Holders Change
+4
Holders Change %
+10.26%
% of All Funds
0.63%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
16
Reduced
10
Closed
7
Calls
$493K
Puts
$496K
Net Calls
-$3K
Net Calls Change
-$65K

CKPT Hedge Fund Activity: Q4 2023 in Review

43 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Checkpoint Therapeutics (CKPT) for Q4 2023, worth a combined $11.2M — up 68% from $6.68M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CKPT positions and 7 closed out — a net gain of 4 holders — while 16 added to existing stakes and 10 trimmed.

The largest buyer was Armistice Capital, adding an estimated $788K. The largest seller was Sabby Management, exiting entirely with an estimated $447K sold.

  • 43 institutional investors held Checkpoint Therapeutics (CKPT) as of Q4 2023, up from 39 in Q3 2023.
  • Funds reported $11.2M of Checkpoint Therapeutics stock for Q4 2023, up 68% quarter-over-quarter.
  • 11 funds opened new Checkpoint Therapeutics positions in Q4 2023 and 7 closed out, a net change of +4 holders.
  • The largest Checkpoint Therapeutics buyer in Q4 2023 was Armistice Capital, an estimated $788K added.
  • The largest Checkpoint Therapeutics seller in Q4 2023 was Sabby Management, an estimated $447K sold.

Based on aggregated 13F filings for Q4 2023.